Across TCGA pan-cancer cohorts, MIR7-2 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated MIR7-2 data layer compared with 9 for mass-spec protein.

The strongest signal is observed in lung squamous cell carcinoma (LUSC), where higher MIR7-2 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated MIR7-2 expression acts as an unfavorable survival marker.

LUSC, SKCM, and PRAD are the cancer types where MIR7-2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUSC	DFS	Median	All	0.231	0.758	.017	18	view →
SKCM	DFS	Median	All	0.088	0.737	<.001	18	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: MIR7-2 tumor-vs-normal RNA expression · all MIR7-2 data types